Lifitegrast
FDA-approved product (solution/drops, ophthalmic), marketed as Lifitegrast, Xiidra.
- Registered studies
- 39
- Lab records
- 0
- Pathogens at ≥40%
- 3 of 4
Chemical structure
Existing / approved use
Documented · FDA, WHO, ChEMBLApproved for
- Dry eye syndrome
- Eye disease
Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗
- WHO therapeutic group
- Other ophthalmologicals
- FDA pharmacologic class
- Lymphocyte Function-Associated Antigen-1 Antagonist FDA label ↗
- Anti-infective classification
- Not classified as an anti-infective.
Repurposing investigation
This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.
AI-predicted activity
AI prediction · nothing measured- MRSA51.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- E. coli44.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
- K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
- M. tuberculosis56.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.
Evidence
Clinical and experimental
Documented evidenceClinical
39registered studies name this medicine, for any condition. See them below.
Experimental
No evidence found
No laboratory measurement against the four pathogens in the ChEMBL records loaded here.
Docking
Computational · nothing measuredDihydrofolate reductase ↗ (E. coli)
Not yet docked: queued in the docking rundetails
KPC-2 carbapenemase ↗ (K. pneumoniae)
Not yet docked: queued in the docking rundetails
Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)
Not yet docked: queued in the docking rundetails
Dihydrofolate reductase ↗ (MRSA)
Not yet docked: queued in the docking rundetails
AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.
Other medicines to investigate
AI prediction · nothing measuredOther repurposing candidates: approved medicines besides Lifitegrast with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.
Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.
- DichlorphenamideExisting use: Glaucoma73.9% AI-predicted activityagainst M. tuberculosisLab records exist2 registered studies
- Tamsulosin HydrochlorideExisting use: Benign prostatic hyperplasia, Prostate carcinoma73.2% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Thiethylperazine MalateExisting use: Allergic disease71.8% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SaquinavirExisting use: HIV infection, HIV-1 infection, Viral disease71.5% AI-predicted activityagainst M. tuberculosis50+ registered studies
- AvacopanExisting use: Anti-neutrophil antibody associated vasculitis, Anti-neutrophil cytoplasmic antibody-associated vasculitis, Granulomatosis with Polyangiitis and 1 more71.3% AI-predicted activityagainst M. tuberculosis26 registered studies
- Lasmiditan SuccinateExisting use: Migraine disorder71.0% AI-predicted activityagainst M. tuberculosisNo documented evidence found
- SotorasibExisting use: Neoplasm, Non-small cell lung carcinoma71.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Vinblastine SulfateExisting use: Classic Hodgkin lymphoma, Fungal infectious disease, Hodgkins lymphoma and 3 more70.8% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Haloperidol DecanoateExisting use: Conduct disorder, Mental or behavioural disorder, Psychosis and 4 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- HydrochlorothiazideExisting use: Angina pectoris, Cardiovascular disease, Chronic kidney disease and 9 more70.1% AI-predicted activityagainst M. tuberculosis50+ registered studies
- TolvaptanExisting use: Autosomal dominant polycystic kidney disease, Cardiovascular disease, Congestive heart failure and 4 more70.0% AI-predicted activityagainst M. tuberculosis50+ registered studies
- Larotrectinib SulfateExisting use: Abdominal Neoplasms, Cancer, Metastasis and 1 more69.2% AI-predicted activityagainst M. tuberculosis5 registered studies
Registered studies
A registration describes a study; it does not establish a positive result.
Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness
NCT03686878 · start 2016-12-16
Registered record
- Registry ID
- NCT03686878
- Conditions
- Contact Lens; Contact Lens Discomfort; Contact Lens Dryness
- Interventions
- Lifitegrast
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-12-16
- Completion
- 2017-07-14
- Enrolment
- 21
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionContact Lens; Contact Lens Discomfort; Contact Lens DrynessInterventionLifitegrastPhasePhase 4Registry statusCompletedEffect of Lifitegrast on Dry Eye Disease Signs and Symptoms
NCT03451396 · start 2016-12-12
Registered record
- Registry ID
- NCT03451396
- Conditions
- Dry Eye
- Interventions
- Lifitegrast
- Study type
- INTERVENTIONAL
- Phase
- Phase 4
- Registry status
- Completed
- Start
- 2016-12-12
- Completion
- 2018-03-15
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry EyeInterventionLifitegrastPhasePhase 4Registry statusCompletedA Study to Evaluate Efficacy and Safety of Lifitegrast in Subjects With Dry Eye (OPUS-3)
NCT02284516 · start 2014-11-06
Registered record
- Registry ID
- NCT02284516
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2014-11-06
- Completion
- 2015-10-05
- Enrolment
- 711
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedA Phase 3 Study to Evaluate the Efficacy of Lifitegrast in Subjects With Dry Eye
NCT01743729 · start 2012-12-07
Registered record
- Registry ID
- NCT01743729
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-12-07
- Completion
- 2013-10-01
- Enrolment
- 720
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedSafety Study of Lifitegrast to Treat Dry Eye
NCT01636206 · start 2012-10-16
Registered record
- Registry ID
- NCT01636206
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2012-10-16
- Completion
- 2014-03-03
- Enrolment
- 332
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedSafety and Efficacy Study of SAR 1118 to Treat Dry Eye Conducted in a Controlled Adverse Environment (CAE) (OPUS-1)
NCT01421498 · start 2011-08-29
Registered record
- Registry ID
- NCT01421498
- Conditions
- Keratoconjunctivitis Sicca; Dry Eye Disease
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 3
- Registry status
- Completed
- Start
- 2011-08-29
- Completion
- 2012-04-28
- Enrolment
- 588
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionKeratoconjunctivitis Sicca; Dry Eye DiseaseInterventionLifitegrast; PlaceboPhasePhase 3Registry statusCompletedA Study Evaluating the Efficacy of SAR 1118 (0.1%, 1.0%, 5.0%) Ophthalmic Solution in Subjects With Dry Eye Conducted in a Controlled Adverse Environment (CAE)
NCT00926185 · start 2009-08-03
Registered record
- Registry ID
- NCT00926185
- Conditions
- Dry Eye
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-08-03
- Completion
- 2010-02-18
- Enrolment
- 230
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDry EyeInterventionLifitegrast; PlaceboPhasePhase 2Registry statusCompletedSAR 1118 in Human Subjects Undergoing Pars Plana Vitrectomy
NCT00936520 · start 2009-08
Registered record
- Registry ID
- NCT00936520
- Conditions
- Diabetic Macular Edema (DME); Pars Plana Vitrectomy
- Interventions
- SAR 1118 0.1%; SAR 1118 1.0%; SAR 1118 5.0%
- Study type
- INTERVENTIONAL
- Phase
- Phase 1
- Registry status
- Terminated
- Start
- 2009-08
- Completion
- 2010-05
- Enrolment
- 30
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionDiabetic Macular Edema (DME); Pars Plana VitrectomyInterventionSAR 1118 0.1%; SAR 1118 1.0%; SAR 1118 5.0%PhasePhase 1Registry statusTerminatedEfficacy Study to Evaluate the Effectiveness of 3 Concentrations of SAR 1118 in Allergic Conjunctivitis
NCT00882687 · start 2009-04-24
Registered record
- Registry ID
- NCT00882687
- Conditions
- Allergic Conjunctivitis
- Interventions
- Lifitegrast; Placebo
- Study type
- INTERVENTIONAL
- Phase
- Phase 2
- Registry status
- Completed
- Start
- 2009-04-24
- Completion
- 2009-05-10
- Enrolment
- 60
As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.
ConditionAllergic ConjunctivitisInterventionLifitegrast; PlaceboPhasePhase 2Registry statusCompleted